Mineralys Therapeutics Inc (NAS:MLYS)

Q4 2025 Mineralys Therapeutics Inc Earnings Call Transcript

Mar 12, 2026 / 08:30 PM GMT

Release Date Price: $26.99 (-3.50%)

Transcript 10-K8-K

Key Points

Positve

The FDA has accepted the NDA for Laundrostat for the treatment of hypertension, with a PDUFA target action date set for December 22, 2026.
Mineralys Therapeutics Inc (MLYS) has completed five positive clinical trials demonstrating clinically meaningful blood pressure reduction and a favorable safety profile.
The company has a strong financial position with cash equivalents and investments of $656.6 million, sufficient to fund operations into 2028.
There is significant market opportunity with over 20 million people in the U.S. affected by uncontrolled and resistant hypertension.
Mineralys Therapeutics Inc (MLYS) is actively engaging in market access planning and payer engagement to ensure a successful launch of Laundrostat.

Negative

The exploratory trial Explore OSA did not demonstrate a clinically meaningful difference on the primary endpoint, AHI, relative to placebo.
R&D expenses remain high, although they have decreased from the previous year, indicating ongoing significant investment in clinical trials.
G&A expenses have increased significantly, driven by higher compensation expenses and professional fees.
There is uncertainty regarding the competitive landscape, with AstraZeneca potentially launching a competing product in the near future.
The company has not yet finalized its commercial strategy, including pricing and direct-to-consumer marketing plans, which could impact the launch of Laundrostat.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MLYS.OQ - Mineralys Therapeutics Inc
Q4 2025 Mineralys Therapeutics Inc Earnings Call
Mar 12, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Minerales Therapeutics 4th quarter in full year 20 conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Dan Ferry of Life Sci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator.

I would

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.